RxDoctor Payments Data

Paige Westmoreland, PA

Physician Assistant · San Angelo, TXNPI 1417519216

Payments from drug & device makers

$3,053in general payments, 2019–2025

Across 156 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$918
  • Johnson & Johnson$440
  • Otsuka America Pharmaceutical, Inc.$398
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$355
  • Lundbeck LLC$236
  • Sunovion Pharmaceuticals Inc.$221
  • plus $485 from 10 others

What the payments were for

  • Food & beverage$3,053100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,053 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$27,104
Medicare patients
67
Services billed
2,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine23$85,890
VraylarCariprazine Hcl32$47,392
RexultiBrexpiprazole13$18,521
Aripiprazole65$7,380
Oxcarbazepine24$3,598
Duloxetine Hcl139$3,116
Quetiapine Fumarate119$2,332
Buspirone Hcl108$1,777
Mirtazapine69$1,621
Trazodone Hcl167$1,589
Ziprasidone Hcl16$1,489
Vilazodone Hcl11$1,442
Sertraline Hcl130$1,416
Quetiapine Fumarate ErQuetiapine Fumarate26$1,344
Bupropion XlBupropion Hcl48$1,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$61$85,89023 claims
AbbVieVraylar$918$47,39232 claims
Otsuka America Pharmaceutical, Inc.Rexulti$398$18,52113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →